Marsha Crochiere
Seminars
Wednesday 7th October 2026
Panel Discussion: Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact
3:10 pm
- How to determine when a biomarker‑enabled strategy truly advances the program, balancing scientific risk, portfolio focus, and capital efficiency?
- What can biotech do to evaluate partnership models that foster innovation while ensuring operational feasibility, sustainable costs, and long-term scalability of CDx?
- When to integrate biomarker considerations into early clinical development without overburdening trial design, patient recruitment, or organizational capacity?
Thursday 8th October 2026
Assessing Histologic Biomarkers of Response to Micvotabart Pelidotin (MICVO), the First-in-Class ADC Targeting the Tumor Extracellular Matrix Protein Extradomain-B of Fibronectin
1:40 pm
- MICVO binds to extradomain-B of fibronectin (EDB+FN) in the tumor extracellular matrix where the linker is cleaved by extracellular cathepsins to allow free auristatin payload to diffuse into and kill cancer cells directly, via the bystander effect, and by eliciting immunogenic cell
- Pyxis Oncology developed an exploratory immunohistochemistry assay and scoring system to measure the intensity and distribution of EDB+FN in the extracellular matrix of the tumor stroma of preclinical and clinical samples
- Biological drivers, in addition to EDB+FN target expression, may confer sensitivity to MICVO, suggesting a multi factorial biomarker approach to understanding tumor responsiveness to treatment
